Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
C2FO marks $300B in funding for businesses as entrepreneurs navigate ongoing credit crunch
Rapid marketplace expansion in the first half of 2023 helped push Leawood-based C2FO — the world’s on-demand working capital platform — past the $300-billion mark in total funding to its customers. This record funding amount reflects invoices paid an average of 31 days early via C2FO’s platform. C2FO gets vital, low-cost capital into customers’ hands…
Froyo with a ’tini twist: Entrepreneur collaboration serves alcoholic frozen yogurt in KC
Kansas City is excited by the new flavor combinations popping up as two entrepreneurs give customers a taste of collaboration, said Isaac Collins, teasing a line of alcoholic frozen yogurt that’s already hitting cups in the metro. Through a partnership with KC-based Brain Freeze Mobile Daiquiri, Collins’ Yogurtini locations have begun a series of happy…
How Meshuggah Bagels ‘built a bakery without a recipe’ — now expanding to Liberty, Lawrence
Pete Linde tested 72 bagel recipes before hitting perfection with number 73, said Janna Linde. She knows because she tried every single test bagel. “Pete worked on that recipe for about a year. He had a notebook and took notes on every little tweak and modification he made. I’d see the big hand mixer come…
Royals preview ballpark of the future: Now they need to decide where to put it
Editor’s note: The following story was published by KCUR, Kansas City’s NPR member station, and a fellow member of the KC Media Collective. Click here to read the original story or here to sign up for KCUR’s email newsletter. The Royals are choosing between a stadium and entertainment district in Kansas City’s East Village or in North Kansas City. The…